Wall Street brokerages predict that Waters Co. (NYSE:WAT) will report $532.71 million in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Waters’ earnings. The lowest sales estimate is $530.00 million and the highest is $536.90 million. Waters posted sales of $497.97 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 7%. The business is scheduled to report its next earnings report before the market opens on Tuesday, April 24th.
According to Zacks, analysts expect that Waters will report full year sales of $532.71 million for the current fiscal year, with estimates ranging from $2.45 billion to $2.46 billion. For the next fiscal year, analysts anticipate that the business will report sales of $2.58 billion per share, with estimates ranging from $2.58 billion to $2.59 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Waters.
Waters (NYSE:WAT) last announced its earnings results on Tuesday, January 23rd. The medical instruments supplier reported $2.51 EPS for the quarter, beating analysts’ consensus estimates of $2.44 by $0.07. The firm had revenue of $687.28 million for the quarter, compared to analysts’ expectations of $671.98 million. Waters had a return on equity of 24.70% and a net margin of 0.88%. Waters’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.21 EPS.
A number of equities research analysts have commented on WAT shares. Zacks Investment Research upgraded Waters from a “hold” rating to a “buy” rating and set a $217.00 target price on the stock in a report on Tuesday, December 26th. Robert W. Baird increased their target price on Waters from $219.00 to $220.00 and gave the company an “outperform” rating in a report on Wednesday, January 24th. ValuEngine cut Waters from a “buy” rating to a “hold” rating in a report on Wednesday, March 7th. Janney Montgomery Scott increased their target price on Waters from $200.00 to $230.00 and gave the company a “buy” rating in a report on Wednesday, January 24th. Finally, Evercore ISI started coverage on Waters in a report on Wednesday, January 3rd. They set an “in-line” rating and a $198.00 target price on the stock. Eleven analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Waters presently has an average rating of “Buy” and an average price target of $205.50.
Shares of NYSE:WAT opened at $202.32 on Friday. The firm has a market cap of $16,018.46, a price-to-earnings ratio of 27.01, a P/E/G ratio of 2.41 and a beta of 0.93. The company has a debt-to-equity ratio of 0.85, a quick ratio of 6.60 and a current ratio of 7.04. Waters has a one year low of $154.36 and a one year high of $220.20.
In related news, SVP Mark T. Beaudouin sold 42,143 shares of the stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $217.21, for a total value of $9,153,881.03. Following the transaction, the senior vice president now directly owns 20,749 shares of the company’s stock, valued at approximately $4,506,890.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Christopher A. Kuebler sold 416 shares of the stock in a transaction on Thursday, March 8th. The stock was sold at an average price of $209.00, for a total value of $86,944.00. Following the completion of the transaction, the director now directly owns 15,327 shares in the company, valued at $3,203,343. The disclosure for this sale can be found here. Insiders have sold 73,794 shares of company stock worth $16,057,538 in the last 90 days. Insiders own 0.98% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of WAT. Ameriprise Financial Inc. raised its position in shares of Waters by 36.5% in the 3rd quarter. Ameriprise Financial Inc. now owns 69,978 shares of the medical instruments supplier’s stock worth $12,563,000 after buying an additional 18,726 shares during the period. JPMorgan Chase & Co. raised its position in shares of Waters by 2.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 133,322 shares of the medical instruments supplier’s stock worth $23,836,000 after buying an additional 2,608 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Waters by 0.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 210,835 shares of the medical instruments supplier’s stock worth $37,848,000 after buying an additional 1,754 shares during the period. Envestnet Asset Management Inc. raised its position in shares of Waters by 11.1% in the 3rd quarter. Envestnet Asset Management Inc. now owns 3,781 shares of the medical instruments supplier’s stock worth $675,000 after buying an additional 377 shares during the period. Finally, Allianz Asset Management GmbH raised its position in shares of Waters by 7.7% in the 3rd quarter. Allianz Asset Management GmbH now owns 4,179 shares of the medical instruments supplier’s stock worth $750,000 after buying an additional 298 shares during the period. 94.48% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/04/13/zacks-brokerages-expect-waters-co-wat-will-announce-quarterly-sales-of-532-71-million.html.
Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.
Get a free copy of the Zacks research report on Waters (WAT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.